Armata Pharma receives $2.5M additional DoD funding for AP-SA02 Phase 3 readiness

Armata Pharmaceuticals, Inc.

Received $2.5M additional non-dilutive funding from U.S. DoD; total DoD award now $28.7M for AP-SA02 development.
Funding supports Phase 3 readiness of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bacteremia.
Company plans to initiate Phase 3 superiority study of AP-SA02 in H2 2026.
DoD funding provided via MTEC and managed by NMRC/NAMD; non-dilutive nature preserves shareholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.